1. Home
  2. SRG vs HUMA Comparison

SRG vs HUMA Comparison

Compare SRG & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seritage Growth Properties

SRG

Seritage Growth Properties

HOLD

Current Price

$3.50

Market Cap

191.5M

Sector

Real Estate

ML Signal

HOLD

Logo Humacyte Inc.

HUMA

Humacyte Inc.

HOLD

Current Price

$1.17

Market Cap

182.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRG
HUMA
Founded
2014
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
191.5M
182.6M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
SRG
HUMA
Price
$3.50
$1.17
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$10.13
AVG Volume (30 Days)
183.5K
5.3M
Earning Date
11-14-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$17,406,000.00
$1,571,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$698.97
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.43
$0.91
52 Week High
$4.56
$4.85

Technical Indicators

Market Signals
Indicator
SRG
HUMA
Relative Strength Index (RSI) 52.96 50.67
Support Level $3.34 $0.91
Resistance Level $3.48 $1.25
Average True Range (ATR) 0.10 0.08
MACD 0.04 0.02
Stochastic Oscillator 78.95 75.00

Price Performance

Historical Comparison
SRG
HUMA

About SRG Seritage Growth Properties

Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.

About HUMA Humacyte Inc.

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: